Relapsed and Refractory
Hepatoblastoma (rrHBL):
A Prospective Registry and Liver Tumors Research Consortium (LTRC)


The Relapsed and Refractory Hepatoblastoma Registry is one of the core initiatives of the Liver Tumor Research Consortium (LTRC), which is a collaboration among physicians and other care providers, scientists, and additional stakeholders (patients, parents), dedicated to gathering data and biological samples from children, adolescents and young adults with liver tumors. The aim of this Registry is to gain a better understanding of rrHBL and develop better treatment options and outcomes for patients everywhere.

Our Goals:

  1. Registry- By filling a critical gap and prospectively collecting data from pediatric patient populations, we will be better able to characterize clinical behavior and treatment for patients with rrHBL.
  2. Database – The registry includes clinical, biological, and radiological databases, enabling researchers to advance investigation into rrHBL tumor biology and diagnostics.
  3. Tumor Model Development- Tumor models are an excellent tool used to study the causes of cancers and an instrumental tool in testing new drugs. Part of the rrHBL registry includes the option to donate tumor tissue for the purpose of the creation of various forms of tumor models, not limited to cell lines (tumors in a dish) and patient derived xenografts (tumors in mice).
  4. Drug Discovery - Through the use of drug screens with developed tumor models, building on investigation into the biology of rrHBL, the LTRC is supportive of advancing the identification of novel drug therapies for patients with rrHBL.